Prof. Dr. J. Wouter Jukema

Professor J. Wouter Jukema is head of the department of cardiology at Leiden University Medical Center (LUMC) in Leiden, the Netherlands and Board Member of the Netherlands Heart Institute, Utrecht, the Netherlands. He is professor of cardiology and medicine since 2005 with a special focus on atherothrombosis and regenerative medicine. He completed his cardiology training at the LUMC and went on to his doctoral thesis at the Netherlands Heart Institute in Utrecht (1996). He completed his training with a fellowship provided by the European Society of Cardiology at the University of Texas Southwestern Medical Center in Dallas, Texas. He is a past established clinical investigator of the Netherlands Heart Foundation and founding director of the Durrer Center for Cardiovascular Research in Amsterdam. He is currently the chairman of vascular medicine at the Leiden University Medical Center as well as co-chairman of the Dutch Atherosclerosis Society. Prof. Jukema has been the principal investigator of several major national and international interventional cardiology and atherothrombosis studies and the holder of multiple major European Union grants. His current research interests, which comprise the majority of topics in his more than 1000 peer-reviewed articles (with many in top journals like New England Journal of Medicine, Lancet, Nature Genetics, Nature Reviews, Science, Circulation, and European Heart Journal), focus on vascular biology, lipids, atherothrombosis, genetics and interventional cardiology in pre-clinical and clinical studies. His Web of Science citation H-index is > 120 with more than 150,000 citations.

Most recent publications

Assessment of myocardial dysfunction in cirrhotic patients: Should we look at the left atrium rather than at the left ventricle?
Groen RA, Ajmone Marsan N, Jukema JW and Coenraad MJ
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D status is unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) concentrations and risk of coronary heart disease, stroke, and all-cause mortality in observational and Mendelian randomisation frameworks.
Procedural and clinical impact of intravascular lithotripsy for the treatment of peri-stent calcification
van Oort MJH, Al Amri I, Bingen BO, Cordoba-Soriano JG, Karalis I, Sanz-Sanchez J, Oliveri F, van der Kley F, Jukema JW, Jurado-Roman A and Montero-Cabezas JM
Use of intravascular lithotripsy (IVL) for treating peri-stent calcification is increasing. However, this indication remains 'off-label'. We aimed to investigate the efficacy and clinical outcomes of in-stent IVL.
Anomalous Aortic Origin of the Right Coronary Artery: Invasive Haemodynamic Assessment in Adult Patients With High-Risk Anatomic Features
Verheijen DBH, Egorova AD, Jongbloed MRM, van der Kley F, Koolbergen DR, Hazekamp MG, Lamb HJ, Jukema JW, Ki├Ęs P and Vliegen HW
Anomalous aortic origin of a right coronary artery (AAORCA) with an interarterial course merits further evaluation; however, robust risk assessment strategies for myocardial ischemia and sudden cardiac death are currently lacking. The aim of this study is to explore the potential role of fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), and intravascular ultrasound (IVUS) in patients with AAORCA.
High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
Reijnders E, van der Laarse A, Jukema JW and Cobbaert CM
As time has come to translate trial results into individualized medical diagnosis and therapy, we analyzed how to minimize residual risk of cardiovascular disease (CVD) by reviewing papers on "residual cardiovascular disease risk". During this review process we found 989 papers that started off with residual CVD risk after initiating statin therapy, continued with papers on residual CVD risk after initiating therapy to increase high-density lipoprotein-cholesterol (HDL-C), followed by papers on residual CVD risk after initiating therapy to decrease triglyceride (TG) levels. Later on, papers dealing with elevated levels of lipoprotein remnants and lipoprotein(a) [Lp(a)] reported new risk factors of residual CVD risk. And as new risk factors are being discovered and new therapies are being tested, residual CVD risk will be reduced further. As we move from CVD risk reduction to improvement of patient management, a paradigm shift from a reductionistic approach towards a holistic approach is required. To that purpose, a personalized treatment dependent on the individual's CVD risk factors including lipid profile abnormalities should be configured, along the line of P5 medicine for each individual patient, i.e., with Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive approaches.